SBRI Healthcare, an Accelerated Access Collaborative initiative, in partnership with the Academic Health Science Networks (AHSNs) and Asthma + Lung UK, has selected my mhealth Limited as one of their grant recipients to support respiratory patients.
The SBRI Healthcare ‘Competition 21, Phase 3 for Real-world Testing and Implementation: Respiratory Diseases’ identifies the most promising innovations that will help the NHS continue to evolve, meet more patient needs whilst addressing some of the biggest healthcare challenges; one of which is respiratory diseases.
With up to half of all hospital beds being occupied by patients with respiratory illnesses, supporting discharges, preventing disease exacerbations and readmissions is key to ensuring the NHS can manage the huge number of patients needing help. myCOPD, a digital therapeutic from my mhealth, can support this.
The funding from SBRI Healthcare will be used to support real-world testing and implementation of my mhealth's platform in respiratory care pathways across the UK. The goal of the project is to measure the clinical and economic benefits of digital therapeutics in respiratory care, which will help to pave the way for widespread adoption across the NHS.
"We are thrilled to have been awarded this funding by SBRI Healthcare, which will allow us to accelerate the adoption of our digital therapeutic platform in the UK. We believe that our platform has the potential to revolutionize respiratory care management"
said Professor Tom Wilkinson, Professor & Honorary NHS Consultant Respiratory Medicine Southampton University Faculty of Medicine and my mhealth's Chief Science Officer and Co-Founder.
"myCOPD is a powerful tool and we are excited to work with healthcare providers in Bristol and Cornwall to demonstrate its impact on patient outcomes and reduce the burden on the NHS. We would like to thank the West of England AHSN for their support throughout the funding process and look forward to working with the NHS and other healthcare partners to bring our digital therapeutic platform to more patients across the UK.
The implementation of myCOPD into respiratory care pathways will be explored in two distinct UK regions, Bristol & Cornwall."
Cheryl Scott, Industry and Innovation Lead at the West of England AHSN added:
"We’re delighted that my mhealth has been successful in securing this funding in order to support people with respiratory diseases and our health and care delivery partners in the West of England. We continue to provide support and look forward to seeing the impacts of the research study.”
my mhealth is also working with NICE to develop the evidence and health economic model required to support the national roll out of my COPD.
If you want to find out more about this project or learn how myCOPD can help your respiratory patients, please get in touch here.
About my mhealth:
Our mission is to change healthcare forever. We do this by empowering patients and clinical teams to manage long-term conditions using digital therapeutics, delivered remotely at a fraction of the traditional cost to patients with Asthma, COPD, Diabetes and Heart Disease. Our digital therapeutics are designed to enhance service delivery, supporting improved patient outcomes, increased patient access and engagement, resulting in improved use of NHS resources.
This work was commissioned and funded by SBRI Healthcare. SBRI Healthcare is an Accelerated Access Collaborative (AAC) initiative, in partnership with the Academic Health Science Networks (AHSNs). The views expressed in the publication are those of the author(s) and not necessarily those of SBRI Healthcare or its stakeholders.